Glenmark Pharmaceuticals Ltd., of Mumbai, India, said its Switzerland-based subsidiary opened a new cGMP-compliant monoclonal antibody manufacturing facility in La Chaux-de-Fonds, Switzerland, to supplement the company's existing in-house discovery and development capabilities and to supply material for clinical development.